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Abstract: Back pain, including low back pain and neck pain, is the leading cause of disability 
worldwide. This type of pain is challenging to treat, since it presents both a nociceptive and a 
neuropathic component. The latter also contributes to the evolution of pain toward chronifica-
tion. Treatment selection should therefore consider the ability to prevent this event. Tapentadol 
is characterized by a unique and innovative peculiar mechanism of action that makes it the first 
representative of a new class of central strong analgesics referred to as MOR-NRI. This molecule 
acts both on the nociceptive and neuropathic components of pain, and it can therefore be effective 
in the treatment of a mixed pain condition such as back pain. This narrative review discusses the 
rationale for the use of tapentadol in both low back pain and neck pain and presents available 
clinical data. Overall, data show that tapentadol prolonged release is a well-grounded treatment 
for chronic back pain, sustained by a strong mechanistic rationale and robust evidence. Given 
also the availability of long-term efficacy and safety data, we believe that this molecule should 
be considered as an elective therapy for chronic back pain.
Keywords: tapentadol, low back pain, neck pain
Introduction
Low back pain (LBP) is one of the most frequent chronic pain conditions worldwide, with 
a lifetime prevalence >70% in western countries and a heavy burden for the healthcare 
system.1–3 Indeed, LBP is now considered the leading cause of disability worldwide. 
Remarkably, more than two out of three patients experiencing acute LBP attacks ultimately 
develop chronic LBP.4 Moreover, chronic LBP is frequently associated with comorbid 
conditions, including depression, panic and anxiety disorders, and sleep disturbances.5
Although sometimes neglected when compared with LBP, neck pain is also a com-
mon disabling disease.6 Indeed, the prevalence of neck pain can be as high as 23%.7 
Therefore, the economic burden of neck pain is also high, mostly due to increased need 
of medical visits, physiotherapy, pharmacological and surgical treatments, working 
days lost, and compensation expenditure.8
Noteworthy, chronic LBP or neck pain – collectively, back pain – results from 
chronification processes occurring over time and involving plastic alterations of the 
involved structures.9–11 Back pain presents in the wide majority of cases (>90%) as 
a neuropathic component.9,12 Proper selection of treatment is therefore of paramount 
importance. In this setting, routine use of classical opioids is not recommended, since 
benefits are small and substantial risks exist, including overdose and addiction potential, 
and poorer long-term outcomes than without use.13
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Tapentadol is a dual μ-opioid receptor (MOR) agonist and 
noradrenaline reuptake inhibitor (NRI), which was rationally 
designed, and represents the first and unique member of a 
new class of analgesic agents, MOR-NRI.14 Remarkably, the 
“μ-load” of tapentadol is ≤40% relative to classical MOR 
agonists. This reduced μ-load results from the combination 
and synergistic interaction of the two mechanisms of anal-
gesic action. Due to this, lower opioid activity is needed to 
reach comparable analgesia and therefore a more favorable 
tolerability profile is achieved, in terms of gastrointestinal, 
respiratory, and endocrinological adverse events.15,16 More-
over, tapentadol shows minimal serotoninergic activity, with 
potential safety advantages over the long term in terms of 
risk of emesis.17
This narrative review discusses the rationale for the use 
of tapentadol in both LBP and neck pain and presents avail-
able clinical data.
Tapentadol in the treatment of LBP
Rationale of use
Chronic LBP is a heterogeneous condition, where both noci-
ceptive and neuropathic pain mechanisms may be involved.5 
In particular, nociceptive pain results from the activation of 
nociceptors as a response to tissue injury and biomechanical 
stress. On the other hand, the neuropathic component arises 
from injury affecting the nerve roots that innervate the spine 
and lower limbs, and pathological invasive innervation of 
the damaged lumbar discs. This latter component has often 
been underestimated when selecting appropriate treatment 
for LBP.5
Indeed, several practice guidelines for the management 
of chronic LBP have been published.18–21 In most cases, they 
advise a multimodal approach for the management of chronic 
LBP, combining pharmacological therapies with nonpharma-
cological approaches. However, these guidelines typically do 
not include specific recommendations for the treatment of 
the neuropathic components of this type of pain. Moreover, 
available guidelines for the treatment of neuropathic pain are 
usually focused on disease other than LBP, such as posther-
petic neuralgia or painful diabetic neuropathy.22–25
Noteworthy, studies of LBP are typically short term (<3 
months duration), and evidence of effectiveness and safety 
associated with long-term treatment is currently limited.5,26 
In addition, few head-to-head trials comparing different 
treatments and combination strategies have been published, 
and therefore, direct comparisons of drug efficacy and toler-
ability are not possible.
Tapentadol prolonged release (PR) has been proven to 
provide a strong analgesic effect, due to its synergic MOR 
and NRI action.9,10,27,28 Remarkably, the different pharma-
cological effects of tapentadol are not synergic in terms of 
adverse effects.29 Noteworthy, these benefits are paralleled by 
improvements in quality of life (QoL).30 Therefore, tapent-
adol PR may be considered a particularly suitable option in 
patients with chronic LBP, given the important neuropathic 
component of this condition. The efficacy of tapentadol in 
this setting is also supported by the results of a Cochrane 
Review – although published in 2015, it also includes studies 
on osteoarthritis – which shows that tapentadol PR is associ-
ated with a reduction in pain intensity compared with placebo 
and oxycodone and presents improved safety compared with 
oxycodone.31 However, the authors of this review pointed out 
that some methodological flaws were present in the studies 
considered, therefore reducing the quality of the results.
Clinical data
The efficacy and safety of tapentadol PR were extensively 
tested in patients with LBP, both in an experimental and in a 
“field-practice” settings, and in comparative studies (Table 1).
In the pivotal trial of tapentadol in LBP, with a random-
ized, double-blind, placebo-controlled design, ~1,000 patients 
were assigned to tapentadol PR 100–250 mg twice daily, 
oxycodone controlled release (CR) 20–50 mg twice daily 
or placebo over 15 weeks (3-week titration period, 12-week 
maintenance period).32 Overall, both tapentadol PR and 
oxycodone significantly reduced average pain intensity, as 
assessed by the numerical rating scale (NRS), vs placebo 
at week 12 and throughout the maintenance period; how-
ever, tapentadol was associated with a lower incidence of 
treatment-emergent adverse events (TEAEs). Indeed, the 
incidence of gastrointestinal TEAEs, including constipation, 
nausea, and vomiting, was 43.7% with tapentadol and 61.9% 
with oxycodone CR. Moreover, the odds of experiencing 
constipation or the composite of nausea and/or vomiting 
were lower with tapentadol PR than with oxycodone CR 
(P<0.001).
In another Phase IIIb study, with an open-label design 
and without a control group, Gálvez et al evaluated the 
effectiveness and tolerability of tapentadol PR in the manage-
ment of severe chronic LBP in patients with poor tolerance 
to opioids.33 Equi-analgesic ratios for tapentadol to strong 
opioids were calculated, and patients switched directly to 
tapentadol. Patients received tapentadol PR 50–250 mg 
twice daily over a 5-week titration and a 7-week maintenance 
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period. Responder rate (ie, reduced intensity of pain by 
NRS) at week 6 was 80.9% (P<0.0001 vs the null responder 
hypothesis rate, <60%), resulting in a positive trial despite 
premature termination. Moreover, reduced intensity of pain 
was maintained up to week 12. The prevalence of adverse 
events was reported as the reason for switching to tapentadol 
– in most cases constipation and nausea – decreased over 
time. Overall, these data show that tapentadol PR provided 
at least comparable analgesia and improved tolerability vs 
strong opioids in patients with severe, chronic LBP. In 2015, 
Baron et al published the results of a randomized, double-
blind study comparing the effectiveness and tolerability of 
tapentadol PR monotherapy vs tapentadol PR/pregabalin 
combination therapy for severe chronic LBP with a neuro-
pathic component.34 All patients had painDETECT “unclear” 
or “positive” ratings and average pain intensity at baseline of 
≥6 on an NRS. Patients were then titrated to tapentadol PR 
300 mg/day over 3 weeks, and those with ≥1-point decrease 
in pain intensity and average pain intensity ≥4 were assigned 
to tapentadol PR (500 mg/day) or tapentadol PR (300 mg/
day)/pregabalin (300 mg/day) for an 8-week comparative 
period. In the per-protocol population, which consisted of 288 
patients, the effectiveness of tapentadol PR was comparable 
to tapentadol PR/pregabalin; similarly, neuropathic pain and 
QoL measures improved in both the groups. Tolerability 
was good, but the incidence of the composite of dizziness 
and/or somnolence was lower with tapentadol PR (16.9%) 
compared with tapentadol PR/pregabalin (27.0%; P=0.0302). 
According to these data, tapentadol PR monotherapy may 
be considered a favorable treatment option for severe LBP 
with a neuropathic component. In the extension phase of 
this trial, a subpopulation with pain intensity <4 continued 
receiving tapentadol PR 300 mg/day during an 8-week, open-
label continuation arm.35 Overall, greater improvements in 
all measures were observed for this selected population. In 
another randomized, controlled, open-label, Phase IIIb/IV 
study by the same group, the effectiveness of tapentadol PR 
was compared with that of oxycodone/naloxone PR in opioid-
naive patients with severe chronic LBP and a neuropathic pain 
component.36 Patients were randomly assigned to tapentadol 
PR 50 mg twice daily or oxycodone/naloxone PR 10 mg/5 
mg. After a 21-day titration, maximum allowed twice-daily 
doses were 250 mg for tapentadol and 40 mg/20 mg for 
oxycodone/naloxone. Target doses were then continued for 9 
weeks. The primary effectiveness endpoint was the change in 
NRS-3 from baseline to final evaluation; the exact repeated 
confidence interval for tapentadol PR minus oxycodone/
naloxone PR was used to establish noninferiority (upper 
limit <1.3) and superiority (confirmatory analyses). For the 
primary effectiveness endpoint (change in pain intensity from 
baseline to final evaluation), tapentadol PR was superior over 
oxycodone/naloxone (P<0.003).36 Pain intensity at baseline 
was 7.6 in both groups; at final evaluation, it was 4.8 with 
oxycodone/naloxone (mean change vs baseline, –2.7) and 
3.9 with tapentadol PR (mean change vs baseline, –3.7).36 
Moreover, improvements in painDETECT and Neuropathic 
Pain Symptom Inventory scores were greater with tapentadol 
PR, and this molecule was associated with a more favorable 
tolerability profile. On these bases, the authors concluded 
that tapentadol PR may be considered a first-line option 
for managing severe chronic LBP with a neuropathic pain 
component.
Several studies have also investigated the effectiveness 
of tapentadol PR for the treatment of LBP in the “field-
practice” setting, although with all the inherent limitations of 
any observational analysis. Ueberall et al analyzed randomly 
selected data of the German Pain Registry, collected over a 
12-week period, of adult patients treated with either tapen-
tadol PR (n=133) or oxycodone/naloxone (n=128).37 The 
primary endpoint was a composite of ≥30% improvement of 
pain, pain-related disability, and QoL and three tolerability 
components (normal bowel function, absence of either central 
nervous system side effects, and TEAE-related treatment 
discontinuation during the observation period). Overall, the 
two treatments were comparable in terms of effectiveness 
and safety. However, this study was judged to be affected by 
major methodological bias,38 and therefore, its results should 
be considered with caution. A retrospective observational 
study was conducted by Guellen-Astete et al, who evaluated 
patients attending the emergency department (ED) due to LBP 
over a period of 24 months.39 Among 732 patients referring 
to the ED, 91 were treated with tapentadol. In the first month 
after the first assessment, reassessments were less frequently 
observed in the tapentadol group, reaching statistical signifi-
cance from day 8 onwards. Patients on tapentadol also had 
a better clinical evolution of pain compared with those who 
did not receive this analgesic drug. In another 6-month “field-
practice” monocentric experience, with a prospective design, 
Notaro evaluated 27 patients treated with tapentadol PR for 
chronic (>1 year in about 90% of patients) severe LBP.40 All 
patients had received previous analgesic therapy; treatment 
with tapentadol PR was started at 100 mg/day and could be 
increased up to 500 mg/day. Tapentadol PR promptly reduced 
the average intensity of pain at rest (–44% at 9 days) and pain 
on movement (–27% at 3 days; P<0.01 for both compari-
sons). Moreover, the neuropathic component of pain, QoL, 
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and health status improved. No relevant safety signals were 
reported. In a long-term prospective experience, Finco et al 
investigated the effectiveness, safety, and tolerability of oral 
formulation of tapentadol PR in 27 patients with refractory 
chronic LBP over a long-term follow-up (up to 51 months).41 
All the patients reported a significant improvement of pain 
intensity and QoL at last follow-up, and, remarkably, no rel-
evant safety concerns were reported. Overall, these results 
further confirm the long-term effectiveness, safety, and toler-
ability of oral tapentadol PR for the treatment of chronic LBP.
The identification of predictive factors of response would 
improve treatment selection and reduce healthcare costs. In 
a retrospective analysis of an open-label study, 46 baseline 
characteristics of the 122 evaluated patients were included in 
statistical prediction modeling.42 Overall, demographic data 
were not relevant for response prediction. The most important 
predictive factors were QoL and functionality. Neuropathic 
symptoms (high painDETECT score) had a positive predic-
tive validity, while painful attacks and classical yellow flags 
(depression, anxiety) were negative predictors of response.
A remarkable new field of investigation is represented 
by the association of nutraceuticals and tapentadol in the 
treatment of LBP.43 In a pilot Italian study, the addition of 
ultra-micronized palmitoylethanolamide to tapentadol led 
to a major reduction in pain intensity, with a good QoL and 
without any serious adverse event.43
Tapentadol in the treatment of neck pain
Neck pain may be caused by several different conditions that 
compress, irritate, and eventually destroy sensitive structures, 
including the annulus fibrosus, posterior longitudinal liga-
ment, and the capsule of the zygapophyseal joints.44 Remark-
ably, relapses and establishment of chronic pain are frequent 
among patients with neck pain and cervical radiculopathy, 
leading to major impairments in QoL, activity limitation, 
and disability. Central sensitization is thought to play a major 
role in the progression to chronic neck pain.9 However, only 
few studies are available on the efficacy of different pharma-
cological treatments for neck pain, and the only published 
recommendations on the pharmacological approach for this 
disease is based on expert opinion.6
On these bases, tapentadol PR has been tested in the 
management of chronic neck pain, given its dual action on 
the nociceptive and neuropathic components of pain.6 In a 
small observational study, Billeci et al evaluated 54 patients 
with moderate-to-severe (mean NRS 8.1) chronic neck 
pain receiving tapentadol PR 100 mg/day; dosage could be 
adjusted according to clinical needs. Over a 12-week period, 
the dosage of tapentadol PR increased up to 204.5±102.8 
mg/day. Mean pain intensity at movement decreased over 
time (mean change at final evaluation vs baseline, –5.9).6 
At baseline, 70% of patients presented a positive neuro-
pathic component, and this percentage decreased to 23% at 
12 weeks; a 35% decrease was evident already at week 2.6 
Tapentadol PR was also associated with an improvement in 
the Neck Disability Index scores (from 55.6±18.6 at baseline 
to 19.7±20.9 at 12 weeks; P<0.01), and with increased range 
of motion in all three planes, particularly in lateral flexion. 
QoL significantly improved, and ~90% of patients rated their 
overall condition as much/very much improved. No patients 
discontinued tapentadol due to side effects and the use of 
other analgesics diminished during the observed period. 
Overall, these findings suggest that tapentadol PR is effective 
and well tolerated in patients with moderate-to-severe chronic 
neck pain and is associated with a relevant improvement of 
movement functionality and QoL.
Conclusion
Back pain, including LBP and neck pain, is the leading cause 
of disability worldwide. This type of pain is challenging to 
treat, since it presents, in the wide majority of cases, as a 
mixed pain characterized by a nociceptive and a neuropathic 
component. The latter also contributes to the chronification. 
Treatment selection should therefore consider the ability to 
prevent pain chronification by acting on the noradrenergic 
axis.
The pharmacological profile of tapentadol, combining 
synergistically MOR agonism and NRI in one molecule, 
appears to be unique, and therefore, this molecule has been 
proposed to be the first-in-class for a new class of centrally 
acting analgesics, namely MOR-NRI.14 Experimental evi-
dence that NRI is a key mechanism that can be predominant 
in chronic LBP reinforces the concept that tapentadol is 
different from classical opioids and may therefore be an a 
priori choice for the treatment of chronic, neuropathic, and 
mixed pain.15,45,46
Clinical data on the efficacy of tapentadol PR in back pain 
are quite solid and do confirm its strong pharmacological 
rationale of use. Moreover, tapentadol PR is well-tolerated, and 
it is associated with a negligible incidence of adverse events 
associated with opioid therapy (eg, constipation and gastroin-
testinal events) and effects on hormonal axes.47 This favorable 
safety profile is of utmost importance, given the frequent need 
of long-term treatment in patients with back pain. To this end, it 
is worth mentioning that tapentadol has a low potential of abuse 
and can be easily titrated and tapered in clinical practice;48,49 
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dedicated studies should further investigate the titration/taper-
ing and exit strategies with tapentadol PR.
In conclusion, tapentadol PR is a well-grounded treatment 
for chronic back pain, sustained by a strong mechanistic 
rationale and robust evidence. Given also the availability 
of long-term efficacy and safety data, we believe that this 
molecule should be considered as the elective therapy for 
chronic back pain.
Key points
•	 Back pain, including LBP and neck pain, is the leading 
cause of disability worldwide.
•	 This pain is challenging to treat, since it usually presents 
as a mixed pain characterized by a nociceptive and a 
neuropathic component. The latter also contributes to 
chronification.
•	 Treatment selection should therefore consider the ability 
to prevent chronification by acting on the noradrenergic 
axis.
•	 Tapentadol is characterized by a unique peculiar mecha-
nism of action, and it is the only member of the MOR-
NRI class of analgesic. This molecule acts on both the 
nociceptive and neuropathic components of pain, and it 
can be therefore effective in the treatment of back pain.
•	 Clinical data on the efficacy of tapentadol PR in back pain 
are quite solid and do confirm its strong pharmacological 
rationale of use.
•	 Tapentadol PR is well tolerated, and it is associated with 
a negligible incidence of adverse events associated with 
opioid therapy (eg, constipation and gastrointestinal 
events). This favorable safety profile is of utmost impor-
tance, given the frequent need of long-term treatment in 
patients with back pain.
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